Compare METC & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | METC | ABUS |
|---|---|---|
| Founded | 2015 | 2005 |
| Country | United States | United States |
| Employees | 900 | 44 |
| Industry | Coal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 983.3M | 815.5M |
| IPO Year | N/A | 2008 |
| Metric | METC | ABUS |
|---|---|---|
| Price | $13.10 | $4.28 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 1 |
| Target Price | ★ $33.94 | $5.00 |
| AVG Volume (30 Days) | 1.8M | ★ 2.1M |
| Earning Date | 02-25-2026 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 13.64 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $6,171,000.00 |
| Revenue This Year | $22.05 | $125.30 |
| Revenue Next Year | $13.17 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $6.30 | $2.71 |
| 52 Week High | $57.80 | $5.10 |
| Indicator | METC | ABUS |
|---|---|---|
| Relative Strength Index (RSI) | 37.39 | 45.06 |
| Support Level | $9.75 | $4.23 |
| Resistance Level | $19.00 | $4.76 |
| Average True Range (ATR) | 1.09 | 0.23 |
| MACD | -0.01 | -0.05 |
| Stochastic Oscillator | 12.28 | 18.44 |
Ramaco Resources Inc is a United States-based company that operates as a pure-play metallurgical coal company with operations in southern West Virginia and southwestern Virginia. Its portfolio includes high-quality metallurgical coal reserves & resources, with a focus on properties such as Elk Creek, Berwind, Knox Creek, and Maben. These properties are strategically located to serve North American blast furnace steel mills and coke plants, as well as international metallurgical coal consumers. Additionally, the company controls mineral deposits in Sheridan, Wyoming, exploring potential opportunities in rare earth elements and coal-to-carbon-based products. The company's two operating segments are Metallurgical Coal segment; and Rare Earths and Critical Minerals.
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.